Navigation Links
OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months
Date:12/10/2009

office-based treatment of urge incontinence, urinary urgency and urinary frequency, symptoms often associated with overactive bladder. Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to these symptoms. Uroplasty sells the Urgent PC system in the United States, Canada, and countries recognizing the CE mark. Outside of the United States, Urgent PC is also indicated for the treatment of fecal incontinence.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in

The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence, symptoms often associated with overactive bladder.

We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information

This press release contains forward-looking statements, which reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. Further, we cannot assure you that we will timely obtain, or even succeed
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
2. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
3. Final Data from Phase 2 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
4. Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy
5. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
6. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
7. Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study
8. Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis
9. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
10. Radiation Reduction in Heart CT Scans Reported in Study
11. Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... Pharmaceuticals International, Inc. (NYSE: VRX and ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with ... indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all ... Medical, Inc. (NASDAQ: SLTM ) ("Solta") at ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: ... on developing topically administered products using its proprietary transdermal ... exploring strategic alternatives aimed at enhancing shareholder value with ... Advisors, a division of KEMA Partners.  The goal ...
... 31, 2011 Nephros, Inc. (OTC Bulletin Board: ... marketing filtration products for therapeutic applications, infection control, and ... Form S-1 for its previously announced rights offering to ... 2011 by the Securities and Exchange Commission. ...
Cached Medicine Technology:Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 2Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 3Nephros Rights Offering Registration Statement Declared Effective 2Nephros Rights Offering Registration Statement Declared Effective 3Nephros Rights Offering Registration Statement Declared Effective 4
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit organization ... published a comprehensive review today examining the current state ... The review calls for improved global surveillance strategies to ... recent outbreak of Ebola in West Africa that has ... of Guinea and Liberia. According to the World ...
(Date:4/17/2014)... NEW YORK (17 April 2014) Population Council scientists and ... is safe, stable, and can prevent the transmission of ... and rectum in animals: HIV, herpes simplex virus 2 ... provides the first data that the gel is effective ... of efficacy in the vagina against all three viruses ...
(Date:4/17/2014)... is less than 40 years away from a food ... governments, according to a top scientist at the U.S. ... human history, food production will be limited on a ... energy," said Dr. Fred Davies, senior science advisor for ... become as politically destabilizing by 2050 as energy issues ...
(Date:4/17/2014)... Johnston, whose work has transformed cancer care in Northern ... European Academy of Cancer Sciences., The Academy, which was ... highly distinguished oncologists and cancer researchers which aims to ... Europe. , Professor Johnston, whose leadership has seen cancer ... of the UK league table to near the top, ...
(Date:4/16/2014)... , PHOENIX, Ariz. April 15, 2014 The ... Arizona philanthropists at their annual Founders Dinner for their ... cancer. The event took place March 28 in Scottsdale. ... & Catherine Ivy Foundation, received TGen,s John S. McCain ...
Breaking Medicine News(10 mins):Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... Focus is system that regulates blood pressure and fluid ... News) -- New research is shedding some light on ... cause miscarriage and death in pregnant women. , "Preeclampsia ... 10 percent of all pregnancies in the United States," ...
... (FA) is a rare and dangerous disease, new laboratory research ... shows it may lead researchers toward clues in more common ... a study published in the Sept. 11 issue of the ... proteins to DNA damage sites is controlled by replication in ...
... the biggest student drinking problems have so far failed to turn ... in the September issue of the Journal of Studies on ... students, alcohol habits showed little change over a dozen years. In ... two weeks; in 2005, 56 percent said the same. And although ...
... blind and visually impaired often rely on others to provide ... with this method is that it doesn,t give them the ... Lahav of Tel Aviv University,s School of Education and Porter ... to the blind, Dr. Lahav has invented a new software ...
... Administration,s (FDA) recent decision to approve the radioimmunotherapy (RIT) ... lymphoma (NHL). "This is welcome news for ... Ph.D., president of SNM and director of nuclear medicine ... "We,ve known for some time that RIT works extremely ...
... Television journalist Veronica ... and now directs her brother,s story to the White House , ... Los Angeles, CA (PRWeb) September 10, 2009 -- After ... brought the tale of her brother Eric,s tragic battle against health care red tape to ...
Cached Medicine News:Health News:Research Seeks Cause of Preeclampsia 2Health News:Replication at DNA damage sites highlights Fanconi anemia and breast cancer proteins 2Health News:Heavy-drinking colleges showing no improvements 2Health News:Virtual maps for the blind 2Health News:Virtual maps for the blind 3Health News:SNM applauds FDA's decision to approve Zevalin 2Health News:Television Journalist Veronica De La Cruz Brings Her Brother's Story from L.A. to White House in Fight for Health Care Reform 2Health News:Television Journalist Veronica De La Cruz Brings Her Brother's Story from L.A. to White House in Fight for Health Care Reform 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: